Taranjit is Head of Medical Device Software Engineering, Cybersecurity and AI at Enhanced Compliance Inc. (ECI). He brings nearly 30 years of experience helping life sciences organizations develop, commercialize, and scale innovative medical technologies across medical devices, diagnostics, software, digital health, artificial intelligence (AI), precision medicine, biotechnology, and clinical laboratories.
Throughout his career, Taranjit has led quality and regulatory transformations for some of the world's most innovative healthcare technology companies, including Verily (Google Life Sciences), Illumina, Caris Life Sciences, Tempus AI, Guardant Health, Grail, Varian Medical Systems, and Sanmina-SCI. He has built global Quality Management Systems (QMS) aligned with FDA QMSR, ISO 13485, EU MDR/IVDR, and other international regulatory requirements while supporting FDA Class III PMA approvals, first-time FDA inspections, and the successful commercialization of software-enabled and AI-driven medical technologies.
Taranjit is recognized for his expertise in Software as a Medical Device (SaMD), Software in a Medical Device (SiMD), cybersecurity, AI governance, digital health, quality systems, software engineering, and regulatory strategy. As one of the first quality leaders at Verily (Google LifeSciences), he helped establish quality and regulatory frameworks for digital health technologies and worked closely with the FDA's Digital Health initiatives to advance practical approaches for regulating emerging software and AI-enabled medical technologies. Today, he continues to focus on helping organizations implement modern, risk-based quality and regulatory frame works that enable innovation while meeting evolving global regulatory expectations.
Taranjit holds a Doctor of Regulatory Science from the University of Southern California and a Master of Science in Electrical Engineering from Simon Fraser University. He has served as adjunct faculty in graduate Regulatory Science programs, authored books on Medical Device Software, and contributed to RAPS' Global Medical Device Regulatory Strategy.